Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer

NCT00098085 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT00098085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00098085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2003
Completion date
Not reported
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small-cell lung carcinoma, pulmonary cancer